CHEST 2021, News
Fluticasone Furoate/Umeclidinium/Vilanterol Therapy and COPD Exacerbations
Which therapy more effectively reduces severe COPD exacerbations: once-daily FF/UMEC/VI or twice-daily ICS/LABA?
Your search for severe copd returned 83 results
CHEST 2021
Nebulized Revefenacin for COPD Appears More Effective in Women vs Men
Researchers conducted subgroup analysis of revenfenacin phase 3 trial data to assess health status improvements in women vs men with moderate to severe COPD.
ATS 2021, News
Dual Bronchodilation vs Triple Therapy Evaluated for Mortality Rates in COPD
Both dual bronchodilation and triple therapy demonstrated similar rates of mortality in patients with moderate to severe COPD at low risk for exacerbations.
AAAAI 2021, News
Asthma, COPD Disease Severity May Increase Risk of Developing Severe COVID-19
Disease severity of both chronic obstructive pulmonary disease (COPD) and asthma may increase the risk of the development of severe coronavirus disease 2019 (COVID-19).
News
ATS Issues Guideline on Home Oxygen Therapy for COPD, ILD
Long-term oxygen therapy strongly recommended for adults with COPD, ILD who have severe chronic resting hypoxemia
CHEST 2020 COPD In-depth
Revefenacin Plus Formoterol Via Nebulization Improves Lung Function Response in COPD
Once-daily revefenacin when administered via a jet nebulizer with formoterol was well tolerated and associated with greater lung function response compared with formoterol alone in patients with COPD.
CHEST 2020 COPD In-depth
Inhaled Corticosteroid Therapy May Reduce Lung Function Decline in COPD
The adjusted rate of decline in predose trough FEV1 during 52 weeks in the
Researchers used a substudy of the Phase 3 ETHOS study to evaluate lung function decline in patients with inhaled corticosteroid-containing therapies vs glycopyrrolate/formoterol fumarate metered dose inhaler.
CHEST 2020 COPD In-depth
Switch to Extra-Fine Inhaled Triple Therapy Improves Regional Ventilation to Small Airways in COPD
Switching from non-extra fine multi-inhaler triple therapy to single-inhaler extra-fine inhaled triple therapy improved regional ventilation to the small airways in patients with COPD.
CHEST 2020 COPD In-depth
Cardiovascular Adverse Event Risk Following a COPD Exacerbation
In the first 30 days following an exacerbation of chronic obstructive pulmonary disease, there is an increased risk of cardiovascular adverse events.
News
Oral Sustained-Release Morphine May Improve Moderate, Severe Breathlessness in COPD
The use of regular, low-dose, oral sustained-release morphine for 4 weeks in patients with COPD and moderate to very severe breathlessness has been shown to improve disease-specific health status.
